local_hospital

Wojewodzki Specjalistyczny Szpital Im Dr Wl Bieganskiego

Address
lock Available on a paid plan

Cardiovascular Diseases and Metabolic Risk

At Wojewodzki Specjalistyczny Szpital Im Dr Wl Bieganskiego in Lodz, research in cardiovascular diseases focuses on major conditions such as acute coronary syndromes, heart failure, and hypertrophic cardiomyopathy, along with high-risk lipid disorders.

  • Studies are assessing new approaches to lower cardiovascular event risk and improve outcomes after heart attack or in people at elevated risk.
  • Trials also examine treatments for heart failure with reduced ejection fraction and symptom relief in hypertrophic cardiomyopathy.
  • Another key area is familial hypercholesterolemia and elevated lipoprotein(a), with the goal of better prevention of future heart disease.

Overall, this site is contributing to studies that test whether newer therapies can reduce complications, improve quality of life, and strengthen long-term cardiovascular protection.

Pulmonary Hypertension and Respiratory Tract Diseases

The hospital has a strong program in pulmonary hypertension and related respiratory tract diseases, including pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, and combined postcapillary and precapillary pulmonary hypertension.

  • Research is evaluating treatments that may improve pulmonary vascular resistance and exercise capacity in people with advanced lung-circulation disorders.
  • Some trials focus on patients with pulmonary hypertension linked to heart failure with preserved ejection fraction, aiming to better control symptoms and hemodynamics.
  • The site is also involved in studies of therapies added to existing care to test safety, tolerability, and overall treatment benefit.

This area reflects an active effort to find more effective options for serious breathing and circulation problems that can be difficult to treat.

Immune System Diseases and Skin Disorders

Within dermatology, the department studies immune system diseases and skin and connective tissue diseases, especially atopic dermatitis and moderate to severe plaque psoriasis.

  • These trials are designed to evaluate new therapies for reducing skin inflammation and improving day-to-day comfort.
  • Some research includes children and adolescents, helping determine whether treatments can be effective and well tolerated in younger patients.
  • The work also supports better understanding of how targeted immune treatments may help control chronic skin disease.

As a dermatology-focused unit, Oddzial Dermatologii, Dermatologii Dzieciecej i Onkologicznej contributes to studies aimed at improving care for both common and more severe inflammatory skin conditions.

Virus Diseases and HIV Research

The site participates in clinical trials on virus diseases, with a particular focus on HIV and HIV-1 infection, including studies in both treatment-naive and virologically suppressed adults.

  • Research is testing whether newer antiviral regimens can provide effective control of HIV while supporting simpler treatment options.
  • Some studies compare switch strategies in people already doing well on therapy, with the goal of maintaining viral suppression.
  • These trials help evaluate convenience, durability of response, and overall treatment effectiveness for long-term HIV care.

This work broadens the site’s infectious disease portfolio by contributing to efforts that improve ongoing management of chronic viral infection.

Inflammation-Driven Cardiometabolic Prevention

Several trials at this Polish hospital are exploring whether targeting inflammation and lipid-related risk can prevent serious events in people with established or emerging cardiovascular disease.

  • Key studies include patients after myocardial infarction or those with high baseline risk for future heart events.
  • Researchers are examining therapies intended to reduce recurrent complications and improve long-term prevention.
  • This work combines interest in cardiology, lipid disorders, and broader metabolic disease risk management.

By focusing on prevention as well as treatment, the site supports research aimed at lowering the burden of major heart and vascular events.

Site Overview

assignment
36
connected trials
corporate_fare
30
sponsors
science
46
IMPs

Activity Indicator

Last 6 months

3
Trials started
0% vs previous period.
3
Trials started 6–12 months ago
36
Total trials linked
Highly Active
trending_flatStable0%
1
1
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 3 of 6 therapeutic areas and 15 of 46 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 44 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
13
Sponsors (total)
30
Active sponsors
13

Sponsor Network

Top 13 by active trials.

lock +12 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +5 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 1 624 other sites in Poland

description
Trial volume
36
Outperforms 92% of sites
public
Therapeutic diversity
6areas
Outperforms 87% of sites
groups
Sponsor diversity
30sponsors
Outperforms 95% of sites

Therapeutic Area Benchmark — Poland

Select a therapeutic area to compare against other sites in Poland.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Poland

Market Share

Country: Poland

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Wojewodzki Specjalistyczny Szpital Im Dr Wl Bieganskiego

lock Showing 1 of 36 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 1 Randomized, Double‑Blind, Placebo‑Controlled Study of BBT001 in Healthy Volunteers and Adults with Atopic DermatitisBambusa Therapeutics Inc.Phase INot Yet Recruiting

IMP list

lock Showing 1 of 46 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Emtricitabine4Unknown2024-02-142026-02-11

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.